elraglusib

Generic: elraglusib·Code: 9-ING-41

elraglusib: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
ACTUATE THERAPEUTICS, INC. (ACTU)Phase 1/Phase 2

FDA Decisions

FDA_MeetingFDA issuing Breakthrough Therapy designation for elraglusib is a Milestone Date trigger that would begin a 20-day warrant expiration period.(ACTU)

Frequently asked questions

Who is developing elraglusib?

elraglusib is being developed by ACTUATE THERAPEUTICS, INC..

What is elraglusib's latest FDA decision?

The most recent tracked FDA decision for elraglusib is FDA_Meeting for FDA issuing Breakthrough Therapy designation for elraglusib is a Milestone Date trigger that would begin a 20-day warrant expiration period..

Get deeper analysis on elraglusib

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    elraglusib — Drug Pipeline, Trials & FDA Status | BioSniper